Adenovirus IgM ELISA Kit

This diagnostic kit is designed to qualitatively detect adenovirus IgM (ADV-IgM) antibodies in human serum using a capture ELISA methodology. The assay employs microplate wells pre-coated with highly specific mouse anti-human IgM (μ chain) antibodies. During the first incubation step, when the patient's serum sample is added to the wells, any IgM antibodies present, including those targeting adenovirus, are selectively captured by the immobilized anti-μ chain antibodies. Unbound serum components, such as IgG antibodies and other proteins, are then thoroughly washed away to eliminate background interference. In the subsequent step, a proprietary ADV antigen-anti-ADV antibody-enzyme conjugate complex is introduced. This conjugate specifically binds to the captured ADV-IgM antibodies, forming a sandwich-like immunocomplex structure: anti-μ chain antibody – ADV-IgM antibody – ADV antigen-anti-ADV antibody-HRP conjugate. Excess unbound conjugate is removed through another washing cycle, ensuring only specific binding complexes remain. The final step involves the addition of TMB (3,3',5,5'-tetramethylbenzidine) substrate, which is catalyzed by the horseradish peroxidase (HRP) enzyme in the immunocomplex to produce a blue color reaction. The addition of stop solution terminates the enzymatic reaction, turning the solution yellow. The intensity of the yellow color, measured as absorbance (A value) using a microplate reader at 450 nm, is directly proportional to the amount of ADV-IgM antibodies present in the sample. A cut-off value, determined through rigorous validation, is used to classify results as positive, negative, or equivocal, enabling reliable detection of acute adenovirus infection. This two-step capture assay ensures high specificity and sensitivity, minimizing cross-reactivity with other viral IgM antibodies and providing a robust tool for clinical diagnosis and epidemiological surveillance.